| Test |
In Range |
Out Of Range |
Units |
Reference |
| Apolipoprotein |
115 |
|
mg/dL |
55 - 140 |
| |
| Comp Metabolic Panel |
|
|
|
|
| Sodium |
138 |
|
mmol/L |
136 - 145 |
| Potassium |
4.3 |
|
mmol/L |
3.5 - 5.1 |
| Chloride |
100 |
|
mmol/L |
98 - 107 |
| |
| Bicarbonate |
32 |
|
mmol/L |
21 - 32 |
| Anion Gap |
6 |
|
mmol/L |
3 - 12 |
| Glucose |
|
109 H |
mg/dL |
70 - 99 |
| BUN |
16 |
|
mg/dL |
7 - 18.0 |
| Creatinine |
1.21 |
|
mg/dL |
0.50 - 1.30 |
| |
| eGFR Other |
|
L 58 |
Units |
> 60 |
| |
Units: mL/min/1.73 m2. Estimated glomerular filtaration rate values are calculated using the CKD-EPI equation. |
| Calcium |
9.3 |
|
mg/dL |
8.5 - 10.1 |
| Total Protein |
7.3 |
|
g/dL |
6.2 - 8.5 |
| Albumin |
4.4 |
|
g/dL |
3.4 - 5.0 |
| Bilirubin, Total |
0.6 |
|
mg/dL |
< 1.1 |
| |
| Alkaline Phosphatase |
94 |
|
U/L |
50 - 136 |
| AST |
|
L 14 |
U/L |
15 - 37 |
| ALT |
28 |
|
U/L |
0 - 60 |
| |
| EBV Ab Panel |
|
|
|
|
| EBV VCA Ab, IgM Qual |
Neg |
|
|
Neg |
| EBV VCA Ab, IgG Qual |
|
Pos |
|
Neg |
| EBV EA Ab, IgG Qual |
Neg |
|
|
Neg |
| EBVNA Ab, IgG Qual |
|
Pos |
|
Neg |
| |
| Ferritin |
67 |
|
ng/ml |
15 - 388 |
| |
| IRON/Iron Binding |
|
|
|
|
| Iron |
107 |
|
ug/dl |
35 - 150 |
| Iron Binding |
332 |
|
ug/dL |
250 - 450 |
| Iron Saturation |
32 |
|
% |
20 - 50 |
| |
| Hemoglobin Alc |
|
|
|
|
| Alc (percent) |
5.5 |
|
% |
4.8 - 5.6 |
| Average Glucose |
111 |
|
mg/dL |
|
| |
eAG = (28.7 * HbAlc) - 46.7 |
| |
| Lipid Profile |
|
|
|
|
| Cholesterol |
|
276 H |
mg/dL |
< 200 |
| Triglyceride |
111 |
|
mg/dL |
< 150 |
| HDL |
94 |
|
mg/dL |
> 40 |
| LDL (calculated) |
|
160 H |
mg/dL |
< 100 |
| Cholesterol:HDL Ratio |
2.9 |
|
|
< 5 |
| VLDL (calculated) |
22 |
|
mg/dL |
5 - 40 |
| |
| Osmolality |
294 |
|
mOsm/kg |
289 - 308 |
| |
| T3 Total |
111 |
|
ng/dL |
87 - 167 |
| TSH |
2.82 |
|
uIU/mL |
0.40 - 4.50 |
| |
| CD57 Lymphocyte |
|
|
|
|
| CD57, CD3, CD8, Flow |
EZ |
|
|
|
| CD57+/CD3-of % lymphs |
8 |
|
% |
1 - 10 |
| CD57+/CD3-of % WDC |
2 |
|
% |
1 - 4 |
| CD57+/CD3-absolute |
84 |
|
cells/uL |
20 - 258 |
| |
| CD57+/CD3-/CD8-of % lymphs |
1 |
|
% |
1 - 5 |
| CD57+/CD3-/CD8-of % WDC |
1 |
|
% |
1 - 3 |
| CD57+/CD3-/CD8-absolute |
32 |
|
cells/uL |
20 - 114 |
| |
| CD57+/CD8-of % lymphs |
3 |
|
% |
1 - 15 |
| CD57+/CD8-of % WDC |
1 |
|
% |
1 - 4 |
| CD57+/CD8-absolute |
32 |
|
cells/uL |
20 - 248 |
| |
| Transforming Growth Factor Beta One |
5676 |
|
pg/mL |
3465 - 13,889 |
| |
| Alpha Melanocyte Stimulatin Hormone |
7.6 |
|
pg/mL |
0 - 100.0 |
| |
| HSV 6 Ab Panel |
|
|
|
|
| HSV 6 Ab IgM |
< 1:20 |
|
|
< 1:20 |
| HSV 6 Ab IgG |
|
1:80 H |
|
< 1:10 |
| |
exznthema subitum. Rises in antibldy titers to HHV-6 have been detected during infection with other viruses. In seroepidemiology studies of the prevalence of exposure using serum screening dilutions of 1:10, the detection of IgG antibody in a mid-life population approaches 100 %. Due to this high prevalence of HHV-6 antibopdy, correlations of single IgfG titers with specific diseases are of little clinical value.
Evidence of acute infection or reactivation of HHV-6 is demonstrated by a significant rise or seroconversion of IgG and IgM titers. |
| |
| Arginine Vasopressin |
1.2 |
|
pg/mL |
1.0 - 13.3 |